These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1693 related articles for article (PubMed ID: 32348166)
1. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166 [TBL] [Abstract][Full Text] [Related]
2. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367 [TBL] [Abstract][Full Text] [Related]
3. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Rossi GP; Sanga V; Barton M Elife; 2020 Apr; 9():. PubMed ID: 32250244 [TBL] [Abstract][Full Text] [Related]
4. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202 [TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236 [TBL] [Abstract][Full Text] [Related]
6. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019). Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182 [TBL] [Abstract][Full Text] [Related]
7. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565 [TBL] [Abstract][Full Text] [Related]
8. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients. Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528 [TBL] [Abstract][Full Text] [Related]
9. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study]. Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120 [TBL] [Abstract][Full Text] [Related]
10. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19. Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137 [TBL] [Abstract][Full Text] [Related]
11. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus]. Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Sanchis-Gomar F; Lavie CJ; Perez-Quilis C; Henry BM; Lippi G Mayo Clin Proc; 2020 Jun; 95(6):1222-1230. PubMed ID: 32376099 [TBL] [Abstract][Full Text] [Related]
13. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Selçuk M; Çınar T; Keskin M; Çiçek V; Kılıç Ş; Kenan B; Doğan S; Asal S; Günay N; Yıldırım E; Keskin Ü; Orhan AL Clin Exp Hypertens; 2020 Nov; 42(8):738-742. PubMed ID: 32569491 [TBL] [Abstract][Full Text] [Related]
14. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. Li J; Wang X; Chen J; Zhang H; Deng A JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209 [TBL] [Abstract][Full Text] [Related]
15. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265 [TBL] [Abstract][Full Text] [Related]
16. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Albini A; Di Guardo G; Noonan DM; Lombardo M Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651 [TBL] [Abstract][Full Text] [Related]
17. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597 [TBL] [Abstract][Full Text] [Related]
18. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19. Tsioufis C; Dimitriadis K; Tousoulis D Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334 [No Abstract] [Full Text] [Related]
19. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. South AM; Brady TM; Flynn JT Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients. Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]